Log in Register

Raising the bar: Implementing the latest LOINC release further supports interoperability

  • Monday, 09 September 2019 13:00
  • Written by 

 The Regenstrief Institute released version 2.66 of the Logical Observation Identifiers Names and Codes (LOINC) on June 21st this year. LOINC is one of the standard terminologies in the 3M Healthcare Data Dictionary (HDD). However, we don’t simply overwrite the old LOINC content with the new release. A LOINC term is a concept in the HDD, with the LOINC code and name as representations (descriptions) linked (“mapped”) to it. Each axis (Component, Property, Timing, System, Scale and Method) of a LOINC term is also a concept in the HDD (or more than one concept if the axis has subparts). The LOINC term concept in the HDD is related to its axis concepts with relationships. These axis concepts could also be part of other standard terminologies, or we could have created relationships between them and concepts from other terminologies, similar to what we did for LOINC. 


An example would be the chemical measured in a LOINC test result. In the HDD, it could be the same concept as a pharmacy ingredient. These pharmacy ingredient concepts would have codes and names from standard and commercial terminologies mapped to them. For instance, all the laboratory measurements for Ibuprofen have a “Has Analyte” relationship to the Ibuprofen medication concept. This Ibuprofen concept has First DataBank, RxNorm and SNOMED CT codes and descriptions mapped to it. The Ibuprofen concept also has relationships to the appropriate drug classes such as non-steroidal anti-inflammatory drugs (NSAIDs), and drug products containing Ibuprofen would have a “Has Ingredient” relationship to it. If LOINC releases a new lab test involving Ibuprofen, the new LOINC concept would also have a “Has Analyte” relationship to the same Ibuprofen concept. Concepts are never deleted in the HDD, and their meaning is never changed. This principle, and the semantic web formed by all the relationships, are the reasons we don’t simply overwrite existing content when we update a standard release into the HDD. 

The HDD relationships are meant to support our customers in their data analysis and data mining work. For example, there are three new antiviral susceptibility genotyping assays for Hepatitis C Virus (HCV) isolates in LOINC 2.66:

92734-3 Voxilaprevir : Susceptibility : Point in Time : Isolate : Ordinal : Genotyping

92735-0 Pibrentasvir : Susceptibility : Point in Time : Isolate : Ordinal : Genotyping

92733-5 Glecaprevir : Susceptibility : Point in Time : Isolate : Ordinal : Genotyping

From LOINC: Voxilaprevir is an HCV NS3/4A protease inhibitor that is active against HCV genotypes 1-6 (“pangenotypic”). In addition, the common resistance-conferring mutations of HCV genotype 1 NS3 have been shown to confer less resistance to Voxilprevir than to other protease inhibitors. Voxilaprevir is used in combination with Sofosbuvir, an NS5B nucleotide inhibitor, and Velpatasvir, an NS5A inhibitor, to treat chronic HCV infection. Pibrentasvir is an HCV NS5A protein inhibitor. It is available in the U.S. as of 2019 in combination with Glecaprevir, an HCV NS3/NS4A protease inhibitor. The combination drug has high efficacy in treating patients with chronic HCV infection caused by the six common genotypes.

These LOINC concepts in the HDD have a “Has Analyte” relationship to the respective medication concepts, which have other standard codes mapped to them:

 LOINC Lab Test  Relationship To  Medication   RxNorm  SNOMED CT
92734-3  Voxilaprevir Susceptibility  Has Analyte  Voxilaprevir 1939323  736536005
92735-0  Pibrentasvir Susceptibility  Has Analyte  Pibrentasvir 1940636 736836002 
92733-5  Glecaprevir Susceptibility  Has Analyte  Glecaprevir  1940635 736837006 

These relationships allow our users to query for the antiviral medication and link from the drug to the lab test, and vice versa. The clinician or investigator could be selecting information based on use of antiviral medication and the success rate tied to the isolate’s genotype; or studies on the incidence of checking a patient’s susceptibility results. We want to enable our users to focus on making use of their data rather than dealing with updating terminologies; this is also why we establish unique concepts and map all appropriate standard codes to them. This way, interoperability is supported—the medication is identified regardless of whether a SNOMED CT or an RxNorm code was used by different systems. In addition to standard terminologies, local codes are also mapped to HDD concepts. For example, local codes from a lab system that does not use LOINC would be mapped to the LOINC concepts in the HDD. These local mappings are another reason why terminology updates in the HDD are never a simple “cut and paste.”

The update work has wrapped up for this version of LOINC. Onward to the next terminology release!

  • 3705
  • Last modified on Tuesday, 26 September 2023 14:34
Pam Banning

Pamela Banning, MLS(ASCP), PMP(PMI) has been a member of the 3M HDD team since 1999. As a certified medical laboratory scientist with the American Society of Clinical Pathology, she worked in a variety of healthcare settings such as doctors’ offices, a rural hospital, a trauma center and a national reference laboratory. She migrated into laboratory system database administration, and was introduced to vocabulary standards during implementation projects for LOINC and SNOMED CT. She continues her service as a founding member of the laboratory LOINC committee and represented our team on the Office of National Coordinator Standards (ONC)/Interoperability Framework work group with past focuses including orders implementation guide development, results implementation guide development, and LOINC order code development. Her presentations on project management of terminology implementations at national industry conferences include poster sessions, roundtables, podium lectures, papers and recorded webinars. Pam currently serves on the FDA’s SHIELD team (Systemic Harmonization and Interoperability Enhancement for Laboratory Data), HL7’s LIVD workgroup (LOINC In Vitro Diagnostics), and as the laboratory LOINC committee co-chair for Regenstrief Institute.